S3 Episode 4: The Future of Antibody-Drug Conjugates in Lung Cancer Treatment

Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.
Relevant disclosures can be found with the episode show notes on Medscape www.medscape.c.... The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress pubmed.ncbi.nl...
TROP-2 Directed Antibody-Drug Conjugates (ADCs): The Revolution of Smart Drug Delivery in Advanced Non-Small Cell Lung Cancer (NSCLC) pubmed.ncbi.nl...
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan pubmed.ncbi.nl...
Gilead Provides Update on Phase 3 EVOKE-01 Study www.gilead.com...
EVOKE-02: A Phase 2 Study of Sacituzumab Govitecan (SG) Plus Pembrolizumab (Pembro) With or Without Platinum Chemotherapy in First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC) ascopubs.org/d...
Datopotamab Deruxtecan Met the PFS Endpoint in Previously Treated NSCLC dailyreporter....
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells pubmed.ncbi.nl...
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial pubmed.ncbi.nl...
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer pubmed.ncbi.nl...
Press Release: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint www.globenewsw...
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm? pubmed.ncbi.nl...
BL-B01D1, a First-in-Class EGFRxHER3 Bispecific Antibody-Drug Conjugate (ADC), in Patients With Locally Advanced or Metastatic Solid Tumor: Results From a First-in-Human Phase 1 Study meetings.asco....